Ellicott City, MD, United States of America

Younus Mia

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: University System of Maryland. Active years: 2013.


 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Younus Mia: Innovator in Immune Response Modulation

Introduction

Younus Mia is an accomplished inventor based in Ellicott City, MD (US). He has made significant contributions to the field of immunology through his innovative research and patenting efforts. His work focuses on developing materials and methods that can modulate immune responses, particularly in the context of autoimmune diseases.

Latest Patents

Younus Mia holds a patent for "Small molecule inhibitors of Lck SH2 domain binding." This invention provides materials and methods for modulating an immune response. The applications of this patent are particularly relevant for treating diseases associated with aberrant immune responses, such as rheumatoid arthritis. His innovative approach has the potential to improve treatment options for patients suffering from autoimmune conditions.

Career Highlights

Younus Mia is affiliated with the University System of Maryland, where he conducts his research. His work has garnered attention for its potential impact on the medical field, particularly in the treatment of autoimmune diseases. With a focus on scientific advancement, he continues to explore new avenues for innovation in immunology.

Collaborations

Younus Mia collaborates with notable colleagues, including Jun Hayashi and Alexander MacKerell. These partnerships enhance the research environment and contribute to the development of groundbreaking solutions in the field of immunology.

Conclusion

Younus Mia is a prominent inventor whose work in immune response modulation holds promise for advancing treatments for autoimmune diseases. His contributions to the field are significant and reflect a commitment to improving patient outcomes through innovative research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…